Market closedNon-fractional

CG Oncology/CGON

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About CG Oncology

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Ticker

CGON

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Irvine, United States

Employees

61

CG Oncology Metrics

BasicAdvanced
$2.2B
Market cap
-
P/E ratio
-$4.78
EPS
-
Beta
-
Dividend rate
$2.2B
57.954
56.757
0.032
0.071
932.165
3.87
3.87
-7.885

What the Analysts think about CG Oncology

Analyst Ratings

Majority rating from 5 analysts.
Buy

CG Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3,380.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
∞%
Net income
-$17M
4.97%
Profit margin
-3,380.00%
-∞%

CG Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 24.14%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Actual
-$4.37
-$0.36
-
Expected
$0.00
-$0.29
-$0.37
Surprise
-∞%
24.14%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for CG Oncology stock?

CG Oncology (CGON) has a market cap of $2.2B as of July 25, 2024.

What is the P/E ratio for CG Oncology stock?

The price to earnings (P/E) ratio for CG Oncology (CGON) stock is 0 as of July 25, 2024.

Does CG Oncology stock pay dividends?

No, CG Oncology (CGON) stock does not pay dividends to its shareholders as of July 25, 2024.

When is the next CG Oncology dividend payment date?

CG Oncology (CGON) stock does not pay dividends to its shareholders.

What is the beta indicator for CG Oncology?

CG Oncology (CGON) does not currently have a Beta indicator.

Buy or sell CG Oncology stock

Buy or sell CG Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing